Sky Bear Technical Standards - Home
Search
×
FR

Placeholder headline

This is just a placeholder headline

TEMA 2026 Edition – Online Subscription Only

$

BUY NOW

Placeholder headline

This is just a placeholder headline

API RP 15SIH, 2nd Edition: Installation and Handling of Spoolable Reinforced Plastic Line Pipe

$

158

BUY NOW

Placeholder headline

This is just a placeholder headline

API RP 754, 4th Edition: Process Safety Performance Indicators for the Refining and Petrochemical Industries

$

393

BUY NOW

Placeholder headline

This is just a placeholder headline

ASME B31.1-2020: Power Piping

$

668

BUY NOW

Placeholder headline

This is just a placeholder headline

ASME B31.1-2022: Power Piping

$

668

BUY NOW

ISO 21474:2022

ISO 21474:2022 In vitro diagnostic medical devices – Multiplex molecular testing for nucleic acids – Part 2: Validation and verification

CDN $192.00

Description

This document gives the general requirements for validation and verification of multiplex molecular tests which simultaneously identify two or more nucleic acid target sequences of interest. This document is applicable to all multiplex methods used for examination using IVD medical devices and laboratory developed tests (LDTs). It provides information for both qualitative and quantitative detection of nucleic acid target sequences.

This document is intended as guidance for multiplex examinations that either detect and/or quantify human nucleic acid target sequences or microbial pathogen nucleic acid target sequences from human clinical specimens.

This document is applicable to any molecular in vitro diagnostic (IVD) examination performed by medical laboratories. It is also intended to be used by laboratory customers, IVD developers and manufacturers, biobanks, institutions, and commercial organizations performing biomedical research and regulatory authorities. This document is not applicable to metagenomics.

NOTE       An examination procedure developed for a laboratory’s own use is often referred to as a “laboratory developed test,” “LDT,” or “in-house test”.

Edition

1

Published Date

2022-05-13

Status

PUBLISHED

Pages

15

Language Detail Icon

English

Format Secure Icon

Secure PDF

Abstract

This document gives the general requirements for validation and verification of multiplex molecular tests which simultaneously identify two or more nucleic acid target sequences of interest. This document is applicable to all multiplex methods used for examination using IVD medical devices and laboratory developed tests (LDTs). It provides information for both qualitative and quantitative detection of nucleic acid target sequences.

This document is intended as guidance for multiplex examinations that either detect and/or quantify human nucleic acid target sequences or microbial pathogen nucleic acid target sequences from human clinical specimens.

This document is applicable to any molecular in vitro diagnostic (IVD) examination performed by medical laboratories. It is also intended to be used by laboratory customers, IVD developers and manufacturers, biobanks, institutions, and commercial organizations performing biomedical research and regulatory authorities. This document is not applicable to metagenomics.

NOTE       An examination procedure developed for a laboratory’s own use is often referred to as a “laboratory developed test,” “LDT,” or “in-house test”.

Previous Editions

Can’t find what you are looking for?

Please contact us at: